Comparison of Real-World Outcomes in Patients With Follicular Lymphoma Treated With BR Versus RCHOP-Like Regimens
In conclusion, this study of real-world patients supports the use of BR and rituximab maintenance for front-line treatment of FL. Further prospective studies are needed to determine the ideal treatment for FL G3A.
Authors
- Kelsey Baron
- Harsh Shah (ORCID: https://orcid.org/0000-0001-6054-5238)
- Boyu Hu (ORCID: https://orcid.org/0000-0001-9848-9497)
- Allison Marie Bock (ORCID: https://orcid.org/0000-0002-3174-8877)
- Eric Anto (ORCID: https://orcid.org/0000-0003-4971-949X)
- Lindsey A. Fitzgerald (ORCID: https://orcid.org/0000-0001-5988-2878)
- Victoria A. Vardell (ORCID: https://orcid.org/0000-0002-8117-1295)
- Lisa M. Pappas (ORCID: https://orcid.org/0000-0001-7874-9116)
- Daniel A. Ermann (ORCID: https://orcid.org/0000-0001-9233-294X)
- John Esther
Institutions
- University of Utah (US)
- Huntsman Cancer Institute (US)
- Utah Department of Health (US)
Publication Details
- Journal
- Clinical Lymphoma Myeloma & Leukemia
- Published
- 2025-04-06
- DOI
- https://doi.org/10.1016/j.clml.2025.03.017
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AbbVie